Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

Dimitris Rigopoulos; Aikaterini Patsatsi; Christina Antoniou; Dimitrios Sotiriadis; Angeliki Roussaki-Schulze; Nadia Boubouchairopoulou; Ioannis Skiadas; Vasillios Tsekouras; Ana Cristina Hernandez Daly

doi:10.4081/dr.2022.9265

Authors

Dimitris Rigopoulos University of Athens Medical School, Athens, Greece.
Aikaterini Patsatsi
apatsats@auth.gr
Papageorgiou General Hospital, Thessaloniki, Greece. https://orcid.org/0000-0001-9616-2001
Christina Antoniou University of Athens Medical School, Athens, Greece.
Dimitrios Sotiriadis Aristotle University of Thessaloniki, Thessaloniki, Greece.
Angeliki Roussaki-Schulze University of Thessaly and University Hospital of Larissa, Larissa, Greece.
Nadia Boubouchairopoulou Pfizer Hellas, Athens, Greece. https://orcid.org/0000-0002-6553-6549
Ioannis Skiadas Pfizer Hellas, Athens, Greece. https://orcid.org/0000-0002-6458-678X
Vasillios Tsekouras Pfizer Hellas, Cyprus Branch, Nicosia, Cyprus. https://orcid.org/0000-0002-1576-6063
Ana Cristina Hernandez Daly Pfizer Hellas, Athens, Greece. https://orcid.org/0000-0001-5013-7281

Etanercept is approved for continuous or intermittent use and flexible dosing in plaque psoriasis (PsO). The objectives of this study were to investigate real-world treatment patterns with etanercept in Greek adults with moderate-to-severe PsO. This non-interventional multicenter study included a retrospective-to-prospective (RP) cohort, previously treated with etanercept for ≥24 months and followed for an additional 6 months, and a biologic-naïve, prospective-only (PO) cohort, followed for 6 months after treatment initiation. Parameters assessed included Psoriasis Area and Severity Index (PASI), percentage of body surface area (BSA) affected, Dermatology Life Quality Index (DLQI), and adverse events (AEs). This study enrolled 123 patients (RP, n = 56; PO, n = 67), who mostly adhered to continuous treatment (RP, 68%; PO, 95%). The two cohorts had similar mean baseline-to-endpoint decreases in PASI (-9.5 vs -10.1) and BSA (-11.9 vs -12.3). The PO-CTP population had a mean DLQI baseline-to-endpoint score decrease of -5.8, which was statistically significant and clinically meaningful. Treatment-emergent AE rates were 58.9% (RP) versus 26.9% (PO). These real-world data suggest a similar effectiveness of continuous and intermittent etanercept treatment in Greek patients with PsO.

Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50. DOI: https://doi.org/10.1016/j.jaad.2008.02.039

Park BS, Youn JI. Factors influencing psoriasis: an analysis based upon the extent of involvement and clinical type. J Dermatol 1998;25:97-102. DOI: https://doi.org/10.1111/j.1346-8138.1998.tb02357.x

European Medicines Agency. Enbrel. Summary of Product Characteristics 2020 Available from:

http://www.ema.europa.eu/docs/en_GB/ d o c u m e n t _ l i b r a r y / E PA R _ -

_Product_Information/human/000262/WC500027361.pdf. Last accessed: May 22, 2020.

Siegfried EC, Eichenfield LF, Paller AS, et al. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol 2010;63:769-74. DOI: https://doi.org/10.1016/j.jaad.2009.10.046

Ortonne JP, Griffiths CEM, Daudén E, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Exp Rev Derm 2008;3:657-65. DOI: https://doi.org/10.1586/17469872.3.6.657

Cassano N, Loconsole F, Miracapillo A, et al. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Talpharanta Plastic Study Group. Int J Immunopathol Pharmacol 2010;23:797-802. DOI: https://doi.org/10.1177/039463201002300314

Gordon KB, Gottlieb AB, Leonardi CL, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006;17:9-17. DOI: https://doi.org/10.1080/09546630500472838

Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007;56:598-603. DOI: https://doi.org/10.1016/j.jaad.2006.09.002

Ortonne JP, Taieb A, Ormerod AD, et al. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol 2009;161:1190-5. DOI: https://doi.org/10.1111/j.1365-2133.2009.09238.x

Griffiths CE, Luger TA, Brault Y, et al. Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study. J Eur Acad Dermatol Venereol 2015;29:468-73. DOI: https://doi.org/10.1111/jdv.12585

Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009;23:1374-82. DOI: https://doi.org/10.1111/j.1468-3083.2009.03321.x

Gelfand JM, Kimball AB, Mostow EN, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008;11:400-7. DOI: https://doi.org/10.1111/j.1524-4733.2007.00251.x

Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010;9:928-37.

Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009;23:896-904. DOI: https://doi.org/10.1111/j.1468-3083.2009.03211.x

Ruiz-Villaverde R, Galan-Gutierrez M, Barabash-Neila R, et al. Efficacy and cost of etanercept in long-term psoriasis: Rational use in clinical practice. J Dermatolog Treat 2016;27:37-42. DOI: https://doi.org/10.3109/09546634.2015.1054776

Moreno-Ramirez D, Ojeda-Vila T, Ferrandiz L. Disease control for patients with psoriasis receiving continuous versus interrupted therapy with adalimumab or etanercept: a clinical practice study. Am J Clin Dermatol 2014;15:543-9. DOI: https://doi.org/10.1007/s40257-014-0095-3

Barrera MV, Habicheyn S, Mendiola MV, et al. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008;18:683-7.

Luger T, Schopf RE, Schwanke A, et al. An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis. J Eur Acad Dermatol Venereol 2016;30:1730-41. DOI: https://doi.org/10.1111/jdv.13673

Segaert S, Ghislain PD, Boone C. An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium). J Dermatolog Treat 2016;27:103-9. DOI: https://doi.org/10.3109/09546634.2015.1055228

Puig L, Camacho Martínez FM, Gimeno Carpio E, et al. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up. Dermatology 2012;225:220-30. DOI: https://doi.org/10.1159/000343605

Rigopoulos D, Gregoriou S, Katrinaki A, et al. Characteristics of psoriasis in Greece: an epidemiological study of a population in a sunny Mediterranean climate. Eur J Dermatol 2010;20:189-95 DOI: https://doi.org/10.1684/ejd.2010.0869

Supporting Agencies

Pfizer

Rigopoulos, D., Patsatsi, A., Antoniou, C., Sotiriadis, D., Roussaki-Schulze, A., Boubouchairopoulou, N., Skiadas, I., Tsekouras, V., & Hernandez Daly, A. C. (2022). Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece. Dermatology Reports, 14(4). https://doi.org/10.4081/dr.2022.9265